Sarepta Therapeutics Announces FDA Approval To Submit NDA For Eteplirsen
May 19, 2015 at 19:05 PM EDT
Shares of Sarepta Therapeutics are up 38% following news that the FDA will allow the company to submit an NDA for Eteplirsen approval.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|